Chronic hepatitis C treated with phlebotomy alone: Biochemical and histological outcome

Digestive and Liver Disease

Volumn 33, Issue 2, 2001, Pages 157-162

  Sartori, M ^a   Andorno, S ^a   Rigamonti, C ^a   Baldoroni, R ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Fibrosis; Iron; Selenium; Trace elements; Venosection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; COPPER; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IRON; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SELENIUM; TRACE ELEMENT; TRANSFERRIN; VIRUS RNA; ZINC;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPPER BLOOD LEVEL; DEPLETION; DISEASE COURSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOCHROMATOSIS; HEPATITIS C; HISTOLOGY; HUMAN; IRON BINDING CAPACITY; LIVER BIOPSY; LIVER FIBROSIS; LIVER LEVEL; LONG TERM CARE; MALE; OXIDATION; PHLEBOTOMY; PREDICTION; SCORING SYSTEM; STAGING; TREATMENT OUTCOME; ZINC BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; BLOOD CHEMICAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LONG-TERM CARE; MALE; MIDDLE AGED; PHLEBOTOMY; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0035075181     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80072-4     Document Type: Article

References (25)

1. Natural history of liver fibrosis progression in patients with chronic hepatitis C
2. Natural history of chronic hepatitis C
3. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C
4. Evaluation of iron status in patients with chronic hepatitis C
5. Role of iron in the natural history and clinical course of hepatitis C disease
6. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effect of dose and duration
7. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
9. Iron and chronic viral hepatitis
10. Can iron depletion therapy ameliorate hepatocellular injury in anti-HCV positive chronic hepatitis?
11. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon
12. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic hepatitis C and excess hepatic iron
13. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy
14. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C
15. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C
16. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon
17. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy
18. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
19. Prediction of risk of liver disease by alcohol intake, sex, and age; a prospective population study
20. Histological grading and staging of chronic hepatitis
21. Iron storage diseases
22. Phlebotomy reduction therapy in hepatitis C
23. Phlebotomy reduces serum procollagen III peptide levels in patients with chronic hepatitis C
24. Deironization in chronic hepatitis C patients previously nonresponsive to interferon improves transaminases but not viral activity
25. Iron reduction therapy: Simply camouflage, or real weapon?